Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
CC transcript
PALATIN TECHNOLOGIES INC (PTN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
09/28/2023 8-K Quarterly results
09/28/2023 10-K Annual Report for the period ended June 30, 2023
08/16/2023 4 SPANA CARL (President and CEO) has filed a Form 4 on PALATIN TECHNOLOGIES INC
Txns: Paid exercise price by delivering 2,331 shares @ $2.19, valued at $5.1k
Paid exercise price by delivering 1,901 shares @ $2.19, valued at $4.2k
Paid exercise price by delivering 2,540 shares @ $2.24, valued at $5.7k
Paid exercise price by delivering 1,280 shares @ $2.24, valued at $2.9k
Paid exercise price by delivering 1,640 shares @ $2.24, valued at $3.7k
Paid exercise price by delivering 1,025 shares @ $2.24, valued at $2.3k
Paid exercise price by delivering 851 shares @ $2.17, valued at $1.8k
Paid exercise price by delivering 698 shares @ $2.17, valued at $1.5k
08/16/2023 4 WILLS STEPHEN T (Executive VP and CFO/COO) has filed a Form 4 on PALATIN TECHNOLOGIES INC
Txns: Paid exercise price by delivering 1,527 shares @ $2.19, valued at $3.3k
Paid exercise price by delivering 1,246 shares @ $2.19, valued at $2.7k
Paid exercise price by delivering 1,670 shares @ $2.24, valued at $3.7k
Paid exercise price by delivering 876 shares @ $2.24, valued at $2k
Paid exercise price by delivering 1,083 shares @ $2.24, valued at $2.4k
Paid exercise price by delivering 677 shares @ $2.24, valued at $1.5k
Paid exercise price by delivering 554 shares @ $2.17, valued at $1.2k
Paid exercise price by delivering 455 shares @ $2.17, valued at $987.4
08/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment"
08/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin Provides Update on VYLEESI® Collaborations · Licensee Fosun Pharma Reports First Commercial Sale in China o First prescription dispensed in Chinese Hainan Province · South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study o 93% of patients enrolled completed the Phase 3 trial in premenopausal patients with Hypoactive Sexual Desire Disorder o Data expected later this year o Supports submission to Korean Ministry of Food & Drug Safety for Marketing Approval CRANBURY, NJ – August 8, 2023 /PRNewswire/ – Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that Fosun Pharma, the licensee of Vyleesi in China, rep..."
08/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®"
08/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin to Participate in Canaccord Genuity’s 43rd Annual Growth Conference Cranbury, NJ, August 4, 2023 /PRNewswire/ – Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will participate at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 5:00 p.m. ET in an Analyst led Fireside Chat. A live webcast of the Fireside Chat will be available on the Investors section of Palatin’s website at http://www.palatin.com . A replay of the webcast will be available for 30 days following the presentation. About Palatin Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that..."
07/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi ® Product Revenue Results"
05/19/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/16/2023 8-K Quarterly results
Docs: "Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update"
05/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023 CRANBURY, N.J., May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 16, 2023, at 11:00 a.m. ET. The conference call will include a review of the company’s operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q3 Fiscal Year 2023 Results Press Release 05/16/2023 at 7:30 a.m. ET Q3 Fiscal Year 2023 Conference Call-Live 05/16/2023 at 11:00 ..."
05/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar CRANBURY, N.J., May 8, 2023 /PRNewswire/ – Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today hosted a key opinion leader webinar presenting data from the Lead-In population of the ongoing PL9643 MELODY-1 Phase 3 clinical trial for Dry Eye Disease. The webinar was moderated by Carl Spana, Ph.D., President & CEO of Palatin, and featured Bruce C. Stouch, Ph.D. and George Ousler, M.S. and Michael B. Raizman, M.D., practicing ophthalmologist and CMO of Palatin. The data highlighted the excellent ocular tolerability of PL9643 eye drops and the broad efficacy on the...",
"Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference"
05/01/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/19/2023 8-K Quarterly results
02/14/2023 SC 13G ARMISTICE CAPITAL, LLC reports a 10% stake in PALATIN TECHNOLOGIES, INC.
12/28/2022 4/A SPANA CARL (President and CEO) has filed a Form 4 on PALATIN TECHNOLOGIES INC
Txns: Bought 5,000 shares @ $2.23, valued at $11.2k
Bought 5,000 shares @ $2.2294, valued at $11.1k
12/28/2022 4/A WILLS STEPHEN T (Executive VP and CFO/COO) has filed a Form 4 on PALATIN TECHNOLOGIES INC
Txns: Bought 2,640 shares @ $2.2, valued at $5.8k
Bought 4,000 shares @ $2.22, valued at $8.9k
Bought 100 shares @ $2.215, valued at $221.5
Bought 3,260 shares @ $2.25, valued at $7.3k
12/27/2022 4 WILLS STEPHEN T (Executive VP and CFO/COO) has filed a Form 4 on PALATIN TECHNOLOGIES INC
Txns: Granted 2,640 shares @ $2.2, valued at $5.8k
Granted 4,000 shares @ $2.22, valued at $8.9k
Granted 100 shares @ $2.215, valued at $221.5
Granted 3,260 shares @ $2.25, valued at $7.3k
12/27/2022 4 SPANA CARL (President and CEO) has filed a Form 4 on PALATIN TECHNOLOGIES INC
Txns: Granted 5,000 shares @ $2.23, valued at $11.2k
Granted 5,000 shares @ $2.2294, valued at $11.1k
12/23/2022 4 DUNTON ALAN W (Director) has filed a Form 4 on PALATIN TECHNOLOGIES INC
Txns: Sold 200 shares @ $2.97, valued at $594
12/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/30/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
Docs: "Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update"
11/02/2022 8-K Quarterly results
11/02/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/25/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/25/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/27/2022 EFFECT Form EFFECT - Notice of Effectiveness:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy